Biotechnology
Simcere and Idorsia enter into a licensing agreement for daridorexant in China
NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the discovery, development and commercialization of small molecules to transform the hori...
2022-11-16 08:32
3357
Island to present at World Antiviral Congress 2022
MELBOURNE, Australia, Nov. 15, 2022 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to advise that CEO and Managing Director, DrDavid Foster will present at the World Antiviral Congress 2022 inSan Diego, USA which ...
2022-11-15 21:00
2249
Nona Biosciences Announces Attendance at PEGS Europe 2022
CAMBRIDGE, Mass., Nov. 15, 2022 /PRNewswire/ -- Nona Biosciences (a wholly-owned subsidiary of HBM Holdings, HKEX: 02142) announced that the Company is attending the 14th Protein and Antibody Engineering Summit (PEGS) in Barcelona, Spain, November 14-16, 2022. The booth is located at #54. Frank ...
2022-11-15 15:57
2194
HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Harbor BioMed (HKEX: 02142) today announced establishment of a wholly-owned subsidiary, Nona Biosciences, to provide next-generation antibody and biotherapeutic solutions to partners from discovery to IND. T...
2022-11-15 12:19
1962
Biotheus has entered into a license and collaboration agreement with Hansoh Pharma for its EGFR/MET bispecific antibody in the Greater China territory
ZHUHAI, China, Nov. 14, 2022 /PRNewswire/ -- Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, announced today that they have entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheu...
2022-11-15 11:16
2156
J INTS BIO, Novel Oral 4th Generation EGFR TKI 'JIN-A02' - Phase 1/2 IND approved by US FDA
- First patient expected in December 2022 SEOUL, South Korea, Nov. 10, 2022 /PRNewswire/ -- J INTS BIO announced on November 9th that it had received approval from the US FDA for its Phase 1/2 clinical trial of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' in patients with advanced non-small ...
2022-11-11 10:30
2314
Harbour BioMed Enters into a License and Collaboration Agreement with Moderna
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) today announced that Nona Biosciences, a subsidiary wholly owned by the Company, had entered into a license and collaboration agreement with ModernaTX, Inc. (NASDA...
2022-11-11 09:03
2538
Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting
- Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 monoclonal antibody,tracking to an investigational new drug (IND) filing in H1:2023 - Three poster presentations showcase preclinical data with three programs developed or discovered in-house,ATG-1...
2022-11-11 08:30
2568
CBC-backed ABio-X appoints pharmaceutical and healthcare veteran Dr. Jeffrey Jonas as CEO
WALTHAM, Mass., Nov. 10, 2022 /PRNewswire/ -- ABio-X, the Massachusetts-based biotech incubation platform focused on transformative medicines and breakthrough technologies, today announced the appointment ofJeffrey Jonas, M.D., as its Chief Executive Officer (CEO). Dr. Jonas brings with him mo...
2022-11-10 21:00
2515
Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
SHANGHAI, Nov. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) appl...
2022-11-10 19:02
2019
Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715
SUZHOU, China, Nov. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("KintorPharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the results from the novel dual c-Myc/GSPT1 degrader GT19715 have been s...
2022-11-10 09:12
2147
ScoliCare Opens its First Clinic in the US
New service will treat scoliosis and hyperkyphosis patients in Florida NAPLES, Fla. , Nov. 8, 2022 /PRNewswire/ -- ScoliCare, Australia's largest provider of non-surgical scoliosis and hyperkyphosis treatment and leading worldwide brace manufacturer (ScoliBrace®), today announced the opening of i...
2022-11-08 23:27
2131
Traditional Chinese Medicine Lianhua Qingwen Attracted Eyes in the Annual National Conference of Pharmaceutical Society of Nigeria
SHIJIAZHUANG, China, Nov. 8, 2022 /PRNewswire/ -- Recently, the 95th National Annual Conference of the Pharmaceutical Society ofNigeria was held in Jos, capital of Plateau State. The theme of the Conference in this year was "Medicine Security in an Unstable Economy", and more than 3,000 doctors a...
2022-11-08 20:25
1677
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO, Nov. 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation fro...
2022-11-07 23:25
2488
Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research--Findings to be Presented at SITC 2022
* Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping. * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development. SEOUL, South Korea, Nov. 7, ...
2022-11-07 21:00
1979
Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting
- Poster with updated Phase Ib TOUCH results suggest selinexor plus GemOx could provide a therapeutic option for heavily pre-treated Stage III/IV patients with relapsed/refractory (R/R) T and NK-cell lymphoma - Online abstract with results from the open-label LAUNCH study demonstrated the encoura...
2022-11-07 14:38
1555
Certa Therapeutics' investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
* Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data * The research demonstrated that treatment with FT011 results in a remarkable...
2022-11-04 20:00
2390
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharm...
2022-11-03 21:10
2019
Yuyu Pharma attendance at European Pharmaceutical Conference
SEOUL, South Korea, Nov. 3, 2022 /PRNewswire/ -- Robert Yu, CEO of Yuyu Pharma,
has been attending biopharmaceutical conferences held inGermany, BIO-Europe and
CPHI. The purpose is to explore opportunities to expand into international
markets, such as Europe.
2022-11-03 21:00
2104
Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation
The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization ...
2022-11-03 19:00
1543
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6494
